BACKGROUND The epidemiologic and clinical characteristics of heart transplant (HTx) recipients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We studied the characteristics of HTx recipients from December 20, 2019, to February 25, 2020, in an effort to understand their risk and outcomes. METHODS All accessible HTx recipients were included in this single-center retrospective study. We collected information on the recipients using a web-based questionnaire as well as the hospital database. RESULTS We followed 87 HTx recipients (72.4% were men, and the average age was 51 years). A total of 79 recipients resided in Hubei, and 57 recipients had a Wuhan-related history of travel or contact. Most took precautionary measures while in contact with suspicious crowds, and 96.6% of the families and communities undertook prevention and quarantine procedures. Four upper airway infections were reported, and 3 of them tested negative for SARS-CoV-2 (the fourth recovered and was not tested). All cases were mild and successfully recovered after proper treatment. Laboratory results of 47 HTx cases within the last 2 months were extracted. Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). Liver and kidney insufficiency was seen in 5 and 6 recipients, respectively. CONCLUSION HTx recipients who practiced appropriate prevention measures had a low rate of infection with SARS-CoV-2 and transition to the associated disease COVID-19. These early data will require confirmation as the pandemic establishes around the world.

中文翻译：

---

描述性调查报告：2019年武汉市冠状病毒爆发期间心脏移植受者的流行病学和临床特征

背景技术在严重的急性呼吸综合征冠状病毒2（SARS-CoV-2）流行期间，心脏移植（HTx）受者的流行病学和临床特征仍不清楚。我们研究了HTx接收者从2019年12月20日到2020年2月25日的特征，旨在了解他们的风险和结果。方法该单中心回顾性研究包括所有可及的HTx受体。我们使用基于网络的调查表以及医院数据库收集了有关接受者的信息。结果我们追踪了87位HTx接受者（男性占72.4％，平均年龄为51岁）。共有79名收件人居住在湖北，其中57名收件人有与武汉有关的旅行或接触史。大多数人在与可疑人群接触时采取了预防措施，有96人。6％的家庭和社区进行了预防和检疫程序。据报告有四例上呼吸道感染，其中三例SARS-CoV-2呈阴性（第四例已恢复，未经检测）。所有病例均为轻度，经适当治疗可成功康复。提取最近两个月内47例HTx病例的实验室结果。其中，21.3％的接受者患有既往淋巴细胞减少症，87.2％的接受者具有他克莫司的治疗浓度（5-12 ng / ml）。分别在5位和6位接受者中发现肝和肾功能不全。结论采取了适当预防措施的HTx受体感染SARS-CoV-2的几率很低，并已转变为相关疾病COVID-19。随着全球大流行的流行，这些早期数据将需要确认。